Long-term behavior of an arterial autograft: a new role for intimal hyperplasia?

International Journal of Microcirculation, Clinical and Experimental
J M BellónJ Buján

Abstract

The long-term behavior of an arterial autograft was studied with special attention to the evolution of intimal hyperplasia. An arterial autograft measuring approximately 5 mm in length was implanted in the right common iliac artery of female Sprague-Dawley rats. Animals were sacrificed at 90, 120, 150, 180, 240, 360, 400, 540 and 730 days after implantation. Grafts were evaluated by optical microscopy, electron microscopy, and morphometry. Myointimal cells were marked using an antiactin monoclonal antibody and studied by transmission electron microscopy. In the long term, the myointima of the arterial wall appeared as a consolidated layer formed by smooth muscle cells of contractile phenotype, abundant extracellular material consisting of clumps of elastin and collagen fibers. Cell maturity and degree of differentiation were demonstrated by the incorporation of antiactin antibody. The medial layer of the grafted segment suffered a marked long-term loss of cells and became an acellular layer sustained by the elastic layers. The adventitial layer was markedly cellular and had abundant vasa vasorum. Morphometry showed that the myointimal layer in the operated territory was not uniform and consisted of tongues of varying thickness....Continue Reading

Citations

Jan 19, 2000·Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery·A Dinas da Gama
May 1, 2012·Annals of Vascular Surgery·Maria Esther Rendal-VázquezCandido Andión Núñez
Sep 2, 2015·The Journal of Surgical Research·Magdalena GewartowskaMalgorzata Frontczak-Baniewicz
Mar 12, 2004·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·G PascualJ Buján

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.